ElendiLabs Logo
Back to Articles

Need Regulatory Help? Try Our Platform

Post your regulatory questions or request quotations from verified pharmaceutical consultants worldwide. Get matched with experts who specialize in your market.

Other

January 20, 2026

Approximately 5 minutes

Differentiation and Classification of Medical Devices in Germany (BfArM)

Differentiation and Classification of Medical Devices in Germany (BfArM)

Differentiation from Other Product Categories

BfArM assists in determining whether a product qualifies as a medical device under Article 2(1) MDR or falls under other regulatory regimes:

  • Medicinal products: Principal mode of action is pharmacological, immunological, or metabolic (Directive 2001/83/EC).
  • Biocides: Intended to destroy or control harmful organisms (Regulation (EU) 528/2012).
  • Cosmetics: Primarily for cleaning, perfuming, protecting, or improving appearance (Regulation (EC) 1223/2009).
  • Food/food supplements: Intended for ingestion with nutritional or physiological effect (Regulation (EC) 178/2002).
  • Other borderline cases: E.g., products with both medical and cosmetic claims.

Manufacturers may request a formal differentiation decision from BfArM if classification is unclear. Differentiation and classification - BfArM

Risk-Based Classification under MDR

Medical devices are classified into four risk classes (I, IIa, IIb, III) based on Annex VIII MDR rules:

  • Rule 1–4: Non-invasive devices (e.g., storage, channeling).
  • Rule 5–8: Invasive devices (short/long-term, surgical).
  • Rule 9–13: Active devices (energy source, diagnostic, therapeutic).
  • Special rules: Absorbable, incorporating medicines/derivatives, or specific uses (e.g., contraception, disinfection).

Classification determines conformity assessment route: self-declaration for low-risk Class I vs. notified body involvement for higher classes.

Borderline and Classification Consultation

  • For uncertain cases, manufacturers can submit a consultation request to BfArM (or relevant authority).
  • Request includes product description, intended purpose, claims, mode of action, and justification.
  • BfArM provides non-binding scientific opinion (binding decision possible in some cases via EU mechanisms).
  • Timelines: Usually 3–6 months; urgent cases may be prioritized.

EU Coordination and MDCG Guidance

  • BfArM participates in MDCG Borderline and Classification Working Group.
  • Decisions align with MDCG guidance documents (e.g., MDCG 2021-24 on classification rules).
  • EU-wide borderline manual and classification examples support consistent application.

Practical Advice for Manufacturers

  • Use MDCG documents and BfArM checklists for self-assessment.
  • Document rationale clearly for regulatory audits.
  • Seek early consultation to avoid compliance issues.
  • Classification impacts clinical evaluation requirements, QMS, and post-market obligations.

Correct differentiation and classification ensure appropriate regulatory scrutiny and patient safety under the EU MDR framework in Germany. Differentiation and classification - BfArM

Ask Anything

We'll follow up with you personally.

100% response rate • Reply within 7 business days

Your email will not be published. We'll only use it to notify you when we respond.

Need Expert Guidance?

Contact us at contact@elendilabs.com / +852 4416 5550